Sistemas biodegradáveis de administração periocular de acetato de prednisolona para tratamento de orbitopatias

• Ano de defesa: 2008
• Autor(a) principal: Ricardo Martins Duarte Byrro
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; UFMG
• Palavras-chave em Português: Tratamento de oftalmopatia de Graves; Acetato de Prednisolona; Polímero biodegradável; Via Periocular; Sistema de liberação de fármacos; Tecnologia de liberação controlada; Medicamentos Administração; Polímeros na medicina; Oftalmologia; Farmácia; Olhos Doenças
• Link de acesso: http://hdl.handle.net/1843/LFSA-7T4JV8

The Graves ophthalmopathy (GO) is the most common extra thyroidian manifestation of the Graves disease. It is characterized by inflammation on orbitary tissues and extra-oculars muscles, leading to eye proptosis, which causes low quality of life and, in some cases, blindness. The GO doesnt have a specific treatment and actually the most common is the corticoid therapy by local (periocular) or systemic shoots. However, this treatment is not well tolerated because of the discomfort caused by the frequent shoots and of some side effects caused by the high corticoid doses. An alternative is the decompression surgery, but it is very aggressive and do not eliminate the disease. The aim of this work was to develop, characterize and evaluate a biodegradable drug delivery prolonged-release, destined to periocular administration of prednisolone acetate for the treatment of GO and others autoimmune orbitopathies. It is intended to reduce the incidence of side effects caused by this drug and to make the treatment easier and specific, reducing the number of administrations when compared to the systemic treatment. The developed systems consists in poli--caprolactone (PCL) and prednisolone acetate microspheres, obtained by de solvent evaporation method. The system characterization by DSC has shown the absence of some detectable physical and chemical interaction between drug and polymer. The morphological analysis by MEV showed the successful obtention of the microspheres and their polymeric matrix degradation in different times during the drug liberation. The in vitro preliminary release profile showed the prolonged-release characteristics of th developed system. The preliminary in vivo study did not detect any local toxicity. In summary, the delivery systems evaluated in the present work can be applied, in the future, for the treatment of GO and other auto immune ophthalmic diseases.